Navigation Links
Ceregene Reports Data From Parkinson's Disease Phase 2b Study
Date:4/19/2013

SAN DIEGO, April 19, 2013 /PRNewswire/ -- Ceregene, Inc. today announced the top-line data from its double-blind, randomized, controlled Phase 2b clinical study of CERE-120 (AAV-neurturin), a gene therapy product designed to deliver the neurotrophic factor neurturin, for Parkinson's disease.   The trial did not demonstrate statistically significant efficacy on the primary endpoint (UPDRS-motor off). However, one of the "key secondary endpoints" (Diary-off score), as defined and prespecified in the Statistical Analysis Plan, did produce statistically significant benefit. The trial also provided further evidence for the safety of CERE-120 and the dosing methods employed. A marked placebo effect was observed in this trial in that both the sham-surgery-control patients and the CERE-120 treated patients showed significant improvement following their surgery.

Fifty-one (51) patients with moderately advanced Parkinson's disease who could not be satisfactorily controlled with conventional Parkinson's medication were enrolled in the study at 11 leading clinical sites throughout the U.S.  Approximately half of the patients received CERE-120 while the other half received sham (placebo) surgery as a control.  Patients were monitored for 15-24 months to assess safety and changes in Parkinson's disease symptoms, using multiple endpoints such as the Unified Parkinson's Disease Rating Scale (UPDRS), Daily Diaries that assess motor function throughout the day, and PDQ-39 (a measure of quality of life), among others. Ceregene continues to analyze the data from this trial to gain as much information as possible.

Jeffrey M. Ostrove , Ph.D., president and chief executive officer of Ceregene, Inc. stated, "We are disappointed that we did not achieve broader statistical significance in this small clinical trial, perhaps due in part to the marked placebo effect noted above.  That said, we at
'/>"/>

SOURCE Ceregene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
2. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
3. Interleukin Genetics Reports Third Quarter 2011 Financial Results
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Nile Therapeutics Reports 2011 Third Quarter Financial Results
6. Pharmasset Reports Fiscal Year End 2011 Financial Results
7. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
8. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
9. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
10. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
11. Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... PETERSBURG, Russia , July 10, 2014 ... Russian Federation Dmitry Medvedev , presented ... biopharmaceutical company BIOCAD . The Company is developing ... scope of MabNext project BIOCAD develops a number of ... cancer and autoimmune diseases. The ceremony took place at ...
(Date:7/10/2014)... PROVO, Utah , July 10, 2014 ... genome annotation and interpretation, today announced an ... sequencing (NGS) analytics for Lineagen,s NextStep Dx ... evaluation of neurodevelopmental and neurological disorders, currently ... chromosomal microarray (CMA) testing service used by ...
(Date:7/10/2014)... 2014   Ceres, Inc . (Nasdaq: ... today financial results for the three months ended May ... Ceres reported that the company and its ... growing season in Brazil, which concluded in June, despite ... evaluation areas for part of the growing season. Yields ...
(Date:7/10/2014)... may help in the fight against terrorism with the ... of explosives with the use of light and special ... and Actuators B: Chemical , the researchers describe a ... concentrations as low as 6.3 ppm (parts per million). ... minutes. , "Traditionally explosives detection has involved looking for ...
Breaking Biology Technology:Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Detecting trace amounts of explosives with light 2
... Diagnostics, a leading developer of biofluid-based molecular diagnostic ... the appointment of David Okrongly, Ph.D., as chief ... medical officer, and Sally Bowden, Ph.D., as director ... of cardiothoracic surgery Harvard University and Michael Manyak, ...
... Glioblastoma is one of the most aggressive forms ... tumor, glioblastoma will often infiltrate the surrounding brain tissue, ... chemotherapy or radiation. Likewise, several mouse models of glioblastoma ... a new study, a team led by scientists at ...
... announced today the launch of Curve™ Image Guided Surgery. ... surgery, is unveiling at the Congress of Neurological Surgeons ... of enhancements based on years of feedback from our ... for Brainlab and has helped to produce the ultimate ...
Cached Biology Technology:Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 2Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 3Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 4Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology 5Nanoparticles seek and destroy glioblastoma in mice 2Nanoparticles seek and destroy glioblastoma in mice 3Brainlab Launches Newest Innovation in Image Guided Surgery Technology 2Brainlab Launches Newest Innovation in Image Guided Surgery Technology 3
(Date:7/13/2014)... more effective treatments for cachexia, a profound wasting of ... cancer patients, raising their risk of death, according to ... been tried to reverse the condition, which may cause ... but none have had great success. , Scientists reporting ... Nature , led by Bruce Spiegelman, PhD, demonstrated that ...
(Date:7/11/2014)... the City of Entiat on Tuesday, July 8, 2014. ... grew to over 1,000 acres by evening. Three outbuildings ... investigation by the Washington Department of Natural Resources. The ... in developing fire control strategies and tactics. Other cooperators ... of Natural Resources, (WA DNR), Bureau of Land Management, ...
(Date:7/11/2014)... scientists have set a "mouse TRAP" to capture the ... recent study published in the Journal of Clinical ... technique called TRAP to extract cellular and genetic information ... scientists at the Rockefeller Institute for Medical Research in ... protein-making machinery, or ribosomes, of the cell type of ...
Breaking Biology News(10 mins):Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3
... River in Washington, D.C. is showing multiple benefits from ... improved water clarity have increased the abundance and diversity ... to direct measurements taken during the 18-year field study. ... the lower Potomac has doubled, the area covered by ...
... YORK, Sept. 7 Reportlinker.com announces that a new ... Biomarkers - technologies,markets and companies ... This report follows the broad definition of ... measured and evaluated as an indicator of normal biological ...
... 2009, newly installed photovoltaic (PV) cells world-wide produced a peak ... 5.8 GW was located in Europe. Similarly to previous years, ... of the world,s new solar systems were installed. By the ... (existing and newly installed) was 16 GW, which is about ...
Cached Biology News:Potomac River: 10-fold increase in native submerged vegetation reflects improved water quality 2Reportlinker Adds Biomarkers - technologies, markets and companies 2Reportlinker Adds Biomarkers - technologies, markets and companies 3Reportlinker Adds Biomarkers - technologies, markets and companies 4Reportlinker Adds Biomarkers - technologies, markets and companies 5Reportlinker Adds Biomarkers - technologies, markets and companies 6Reportlinker Adds Biomarkers - technologies, markets and companies 7Reportlinker Adds Biomarkers - technologies, markets and companies 8Reportlinker Adds Biomarkers - technologies, markets and companies 9Reportlinker Adds Biomarkers - technologies, markets and companies 10Reportlinker Adds Biomarkers - technologies, markets and companies 11Reportlinker Adds Biomarkers - technologies, markets and companies 12Reportlinker Adds Biomarkers - technologies, markets and companies 13Reportlinker Adds Biomarkers - technologies, markets and companies 14Reportlinker Adds Biomarkers - technologies, markets and companies 15Reportlinker Adds Biomarkers - technologies, markets and companies 16Reportlinker Adds Biomarkers - technologies, markets and companies 17Reportlinker Adds Biomarkers - technologies, markets and companies 18Reportlinker Adds Biomarkers - technologies, markets and companies 19Reportlinker Adds Biomarkers - technologies, markets and companies 20Three-quarters of new solar systems worldwide were installed in the EU in 2009 2Three-quarters of new solar systems worldwide were installed in the EU in 2009 3
BI-1 Polyclonal Antibody Storage Temperature: -20C Shipping: gel pack Shelf-Life: 12 months...
... cells of embryonal carcinoma of testis and ovary ... like seminoma. Glandular epithelium of yolk sac tumor ... cells of stomach and acini cells of pancreas ... Epitope: Carbohydrate portion on human embryonal carcinoma ...
... Endothelin-1 (human, porcine) Endogenous potent ... ETA receptor and modulates vascular tonus. ET-1, ... three distinct endothelin genes. ET-2 and ET-3 ... two and six amino acids, respectively. All ...
HP 1 alpha Immunogen: Synthetic peptide between amino acids 1-100 of the human HP 1 alpha protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Biology Products: